A phase II trial of pemetrexed in patients with metastatic renal cancer.
- 1 January 2003
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 21 (3) , 353-358
- https://doi.org/10.1023/a:1025480914273
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.2002
- Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumorsAnnals of Oncology, 2000
- Epidemiologic aspects of renal cell cancer.2000
- Interferon in metastatic renal cell carcinoma.2000
- Interleukin-2 in the treatment of renal cancer.2000
- A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationCancer Chemotherapy and Pharmacology, 1999
- Roles of folylpoly-γ-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: An overview1999
- Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.1999
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 1998
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992